As I wrote before, TNBC growth is very fast and chemotherapy doesn't always work well.
At SABCS2011, Japanese great research was shown.
Dr. Ohtani said combination chemotherapy, paclitaxel and FEC, could work as neo-adjuvant chemotherapy to TNBC patients.
エストロゲン受容体（ER）とプロゲステロン受容体（PgR）、HER2が全て陰性のトリプルネガティブ乳癌（TNBC）は予後不良といわれるが、術前補助化学療法によって病理学的完全奏効（pCR）に達した患者の予後は良好であることが日本人データの解析で明らかになった。広島市民病院乳腺外科の大谷彰一郎氏らが、サンアントニオ乳癌シンポジウム2011で発表した。
http://medical.nikkeibp.co.jp/leaf/all/gakkai/sp/sabcs2011/201112/522818.htm
Recently, a lot of molecular targeted drugs were released.
These drugs work well to some patients and contribute to decrease the mortality.
However, these drugs are more expensive than usual anti-cancer drugs.
If usual anti-cancer drugs are available for the treatment, I think to save the cost of medical care, and to increase the benefit of many patients.
I think his research could point the new direction of TNBC treatment, so I'm proud to be the same Japanese.
